m |
|||
Line 47: | Line 47: | ||
<ul class="dropdown-menu"> | <ul class="dropdown-menu"> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Parts">Parts</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Parts">Parts</a></li> | ||
− | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Basic_Part"> | + | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Basic_Part">Basic Parts</a></li> |
− | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Composite_Part"> | + | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Composite_Part">Composite Parts</a></li> |
− | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Part_Collection"> | + | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Part_Collection">Part Collection</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 58: | Line 58: | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Human_Practices">Overview</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Human_Practices">Overview</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Silver">Societal Issues of CRISPR/Cas9</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Silver">Societal Issues of CRISPR/Cas9</a></li> | ||
+ | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Human_Practices/GMO_Regulation">GMO regulation</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Gold">Responsible Research and Innovation</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/HP/Gold">Responsible Research and Innovation</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Integrated_Practices">Integrated Practices</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Integrated_Practices">Integrated Practices</a></li> | ||
<li><a href="https://2016.igem.org/Team:Paris_Saclay/Engagement">Engagement</a></li> | <li><a href="https://2016.igem.org/Team:Paris_Saclay/Engagement">Engagement</a></li> | ||
− | |||
</ul> | </ul> | ||
</li> | </li> |
Revision as of 15:28, 12 October 2016